Given a context passage, generate a question from the passage such that its answer is shortest continous span from the passage.

Q: The Battle of Milne Bay (25 August -- 7 September 1942), also known as Operation RE by the Japanese, was a battle of the Pacific campaign of World War II. Elite Japanese naval troops, known as Kaigun Rikusentai (Special Naval Landing Forces), with tank support attacked the Allied airfields at Milne Bay that had been established on the eastern tip of New Guinea.

A: On what date did Battle of Milne Bay end?
****
Q: Hoping to rebound from their three-game losing streak, the Raiders flew to Dolphin Stadium for a Week 11 duel with the Miami Dolphins. In the first quarter, Oakland trailed early as Dolphins WR Ted Ginn, Jr. got a 40-yard TD run. In the second quarter, the Raiders responded with kicker Sebastian Janikowski getting a 21-yard field goal. In the third quarter, Oakland started to catch up as DE Jay Richardson sacked QB Chad Pennington in his own endzone for a safety. Miami would answer with RB Patrick Cobbs getting a 10-yard TD run. In the fourth quarter, the Raiders took the lead as Janikowski got a 37-yard field goal, along with WR Johnnie Lee Higgins returning a punt 93 yards for a touchdown. However, the Dolphins sealed Oakland's fate as kicker Dan Carpenter nailed a 38-yard field goal.

A: Which player scored a safety?
****
Q: The ubiquitin-proteasome pathway is involved in intracellular protein turnover, and its function is crucial to cellular homeostasis. First synthesized as probes of proteolytic processes, proteasome inhibitors began to be thought of as potential drug candidates when they were found to induce programmed cell death preferentially in transformed cells. They made their first leap into the clinic to be tested as therapeutic agents 10 years ago, and since then, great strides have been made in defining their mechanisms of action, their clinical efficacy and toxicity, and some of their limitations in the form of resistance pathways. Validation of the ubiquitin-proteasome pathway as a target for cancer therapy has come in the form of approvals of the first such inhibitor, bortezomib, for relapsed/refractory multiple myeloma and mantle cell lymphoma, for which this agent has become a standard of care. Lessons learned from this first-in-class agent are now being applied to the development of a new generation of proteasome inhibitors that hold the promise of efficacy in bortezomib-resistant disease and possibly in a broader spectrum of diseases. This saga provides a salient example of the promise of translational medicine and a paradigm by which other agents may be successfully brought from the bench to the bedside.

A:
Which is the target of bortezomib used in cancer therapy?
****